KBC Group NV Has $129,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

KBC Group NV boosted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 75.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,334 shares of the company’s stock after purchasing an additional 2,731 shares during the period. KBC Group NV’s holdings in Denali Therapeutics were worth $129,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DNLI. CWM LLC raised its holdings in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares in the last quarter. Quest Partners LLC bought a new position in Denali Therapeutics in the 3rd quarter worth approximately $73,000. Assetmark Inc. lifted its holdings in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after buying an additional 580 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after acquiring an additional 920 shares during the period. Finally, MONECO Advisors LLC grew its stake in shares of Denali Therapeutics by 4.6% in the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock worth $265,000 after acquiring an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $22.25 on Friday. The stock has a market capitalization of $3.20 billion, a P/E ratio of -8.06 and a beta of 1.43. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The stock has a fifty day moving average of $22.25 and a 200-day moving average of $24.83.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the business earned ($0.72) earnings per share. Equities research analysts forecast that Denali Therapeutics Inc. will post -2.74 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In other news, insider Carole Ho sold 12,255 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the sale, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ryan J. Watts sold 29,266 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now directly owns 260,721 shares in the company, valued at $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock worth $973,442 in the last ninety days. Company insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DNLI. JPMorgan Chase & Co. cut their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, January 7th. Jefferies Financial Group increased their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. HC Wainwright cut their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. The Goldman Sachs Group dropped their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Finally, Robert W. Baird assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price objective on the stock. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $38.00.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.